According to a recent LinkedIn post from HERVolution Therapeutics, the company has added Dr. László B. Tankó to its Scientific Advisory Board. The post notes his prior role as chief medical officer at obesity-focused startup Six Peaks Bio, which was acquired by AstraZeneca in late 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also highlights Dr. Tankó’s 25-plus years of clinical leadership at Novartis, Bayer, and Ferring. This background appears positioned to support the advancement of HERVolution’s lead program, IPT-001, toward planned first-in-human trials in metabolic disease later this year.
As described in the post, IPT-001 is characterized as a potentially first-in-class immunotherapy based on a redesigned HERV-K antigen. The therapy is suggested to target aging-related diseases by stimulating senolytic immune responses, either as a monotherapy or in combination with other agents.
For investors, the appointment of an experienced clinical executive and CMO with recent M&A exposure may signal preparation for more advanced development and potential partnering activity. If IPT-001 progresses into clinical trials on the indicated timeline and demonstrates favorable data, it could strengthen HERVolution’s positioning in the cardiometabolic and aging-related disease segments.